Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Jennerex Out-Licenses China Rights for Cancer Drug to Lee’s Pharma

publication date: Nov 19, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Jennerex, Inc., a clinical-stage biotherapeutics company with a novel virus-based treatment for cancer, has licensed the China rights for JX-594 to Lee’s Pharmaceuticals. Jennerex is headquartered in San Francisco, though its R&D operations are in Ottawa, Canada. JX-594 is currently undergoing a Phase II trial to treat hepatocellular carcinoma (HCC), an urgent unmet need in China. More details...

Stock Symbol: (HKEX: 8221)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...